A preclinical study conducted by a joint team from Switzerland has found that treatment outcomes for glioblastoma patients improve considerably if they receive immunotherapy before undergoing surgery to remove the tumors, instead of first having the tumors surgically removed and then receiving immunotherapy. This research, which appears to challenge the current standard of care, could have significant implications for how this aggressive form of brain cancer is treated in the future.
The study's findings are particularly relevant given the poor prognosis associated with glioblastoma, a type of brain tumor that is notoriously difficult to treat. Standard treatment typically involves surgical resection followed by radiation and chemotherapy, but recurrence is common. The new evidence suggests that the timing of immunotherapy relative to surgery may be a critical factor in improving patient outcomes. By administering immunotherapy preoperatively, the immune system may be better primed to recognize and attack tumor cells, potentially reducing the risk of recurrence and improving overall survival.
This preclinical study is likely to give enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) plenty to think about as they continue to develop novel immunotherapies for cancer. Calidi Biotherapeutics is focused on developing next-generation oncolytic viral therapies, and these findings could influence the design and timing of their clinical trials. If the results are replicated in human studies, it could lead to a paradigm shift in the management of glioblastoma, where neoadjuvant (pre-surgery) immunotherapy becomes a standard part of the treatment regimen.
The implications extend beyond glioblastoma. The concept of using immunotherapy before tumor resection may apply to other solid tumors as well, as the immune system's ability to mount a robust anti-tumor response could be enhanced when the primary tumor is still present. This approach, known as neoadjuvant immunotherapy, has already shown promise in other cancer types, such as melanoma and lung cancer. The current study adds to the growing body of evidence that the timing of immunotherapy is crucial.
According to the researchers, the mechanism behind this improved outcome may involve the presence of the tumor itself, which can serve as a source of antigens to stimulate a stronger immune response. When the tumor is removed first, the immune system may not have been adequately exposed to these antigens, leading to a less effective response to subsequent immunotherapy. By giving immunotherapy first, the immune system is given the opportunity to recognize the tumor as foreign and generate a memory response that can persist even after the tumor is surgically resected.
While these findings are promising, they are still at the preclinical stage, and further research is needed to confirm their applicability in humans. Clinical trials will be essential to determine the optimal timing, dosing, and patient selection for neoadjuvant immunotherapy in glioblastoma. Nevertheless, this study underscores the importance of considering the sequence of treatment modalities and provides a strong rationale for exploring this approach in clinical settings.
For the biotech industry, this research highlights the potential of immunotherapy to be integrated into the standard of care in novel ways. Companies developing immunotherapies, such as Calidi Biotherapeutics, may need to consider the timing of their therapies relative to surgery in their development programs. As more data emerges, it could lead to more personalized treatment strategies for patients with glioblastoma and potentially other cancers.
